Written by Aditya Raghunath at The Motley Fool Canada
Canadian investors should consider holding stocks in recession-resistant sectors such as utilities or healthcare to shield themselves from underlying market volatility. In this article, I have identified three top TSX healthcare stocks you can invest in right now. Let’s see why.
Valued at a market cap of $600 million, Knight Therapeutics (TSX:GUD) is a specialty pharmaceutical company that develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally.
It has increased sales from $1 million in 2015 to $328.2 million in 2023. In the last 12 months, it has reported revenue of $348.6 million. Earlier this year, Knight Therapeutics disclosed plans to acquire Paladin Labs from Endo for $100 million plus $20 million for inventory, with potential milestone payments of up to $15 million. The transaction represents a symbolic reunion, as Knight was initially spun off from Paladin in 2014.
The acquisition adds $70 million in annual revenue from a diversified portfolio of over 40 pharmaceutical products. Knight’s management expects the deal to be immediately EBITDA (earnings before interest, tax, depreciation, and amortization)-accretive, with additional synergies anticipated in 2026.
Knight will fund the acquisition from its existing cash reserves, which stood at $151 million at the end of the third quarter (Q3) of 2024. Canada will account for 25% of Knight’s total business following the acquisition.
Valued at a market cap of $571 million, Kneat.com (TSX:KSI) designs, develops, and supplies software for data and document management within regulated environments in the United States, Ireland, Canada, and internationally. It offers Kneat Gx platform, an application focused on validating lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.
In Q4 of 2024, Kneat reported revenue growth of 40% year over year to $13.7 million, driven by a 41% increase in SaaS (software-as-a-service) revenue to $12.5 million. Annual recurring revenue (ARR) jumped 60% to $59.7 million, with an impressive $10 million in new ARR added in the quarter alone.
“We are pleased to report that we closed the year with fourth-quarter numbers that are in keeping with 2024 as a whole, with both the three-month and full-year period showing strong growth in revenue, growth and operating margins,” said Chief Executive Officer Eddie Ryan.
Since its last earnings call, Kneat.com announced four strategic customer wins across various life sciences segments, including pharmaceutical manufacturing, consumer products, medical devices, and engineering services. Notably, engineering firm Altan will use Kneat’s platform both internally and for its customers.
Gross profit for Q4 grew 48% year over year to $10.4 million, while gross margins expanded to 75%. Comparatively, operating expenses increased by just 10% year over year, showcasing a focus on operational efficiency.
Kneat continued to enhance its platform and expand its partner program, adding global systems integrator Capgemini. It is also incorporating artificial intelligence capabilities to drive efficiencies for both internal operations and customer workflows.
The final TSX healthcare stock on the list is Andlauer Healthcare (TSX:AND), a profitable company valued at $1.5 billion by market cap. It is a supply chain management company that provides a platform of third-party logistics and specialized transportation solutions for the healthcare sector in the U.S. and Canada.
Andlauer Healthcare reported a record annual revenue of $650.5 million in fiscal 2024, maintaining a strong EBITDA margin of 25.3%. Its Canadian specialized transportation network grew 6.3% in Q4, driven by increased pharmaceutical and biologics client volumes.
While Canadian operations showed solid growth, the company’s U.S. truckload businesses faced headwinds from what management called “the Great Freight Recession,” with ground transportation revenue down 17% in Q4 year over year.
Andlauer raised its quarterly dividend to $0.12 per share and remains active in share repurchases, having repurchased 266,000 shares for $10.4 million under its current buyback program.
Priced at 21 times forward earnings, the TSX stock trades at a discount of almost 30% to consensus price targets.
The post 3 Top Healthcare Sector Stocks for Canadian Investors in 2025 appeared first on The Motley Fool Canada.
Before you buy stock in Andlauer Healthcare Group Inc., consider this:
The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Andlauer Healthcare Group Inc. wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.
Consider MercadoLibre, which we first recommended on January 8, 2014 … if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,058.57!*
Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 38 percentage points since 2013*.
See the Top Stocks * Returns as of 2/20/25
More reading
Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Andlauer Healthcare Group and Kneat.com, Inc. The Motley Fool has a disclosure policy.
More Stories
CHAI’s AI oversight ambitions falter with scrapped AI labs
Nutrition in healthcare brings opportunity for industry growth and innovation
Lewis and Clark County job industry sees biggest growth in healthcare